Total Payments
$2,661
2024 Payments
$438.83
Companies
20
Transactions
114
Medicare Patients
5,511
Medicare Billing
$945,021
Payment Breakdown by Category
Food & Beverage$2,447 (92.0%)
Education$213.99 (8.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,447 | 111 | 92.0% |
| Education | $213.99 | 3 | 8.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $666.52 | 30 | $0 (2024) |
| Merck Sharp & Dohme LLC | $396.68 | 24 | $0 (2024) |
| Gilead Sciences, Inc. | $303.68 | 13 | $0 (2024) |
| ABBVIE INC. | $264.45 | 8 | $0 (2024) |
| Insmed, Inc. | $246.49 | 6 | $0 (2021) |
| Paratek Pharmaceuticals, Inc. | $242.02 | 6 | $0 (2024) |
| Allergan, Inc. | $133.26 | 9 | $0 (2020) |
| Ferring Pharmaceuticals Inc. | $125.00 | 1 | $0 (2024) |
| Astellas Pharma US Inc | $84.33 | 4 | $0 (2019) |
| Theravance Biopharma, Inc. | $32.78 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $438.83 | 10 | Ferring Pharmaceuticals Inc. ($125.00) |
| 2023 | $313.46 | 7 | AbbVie Inc. ($125.07) |
| 2022 | $318.91 | 9 | Paratek Pharmaceuticals, Inc. ($110.41) |
| 2021 | $184.42 | 5 | Insmed, Inc. ($113.99) |
| 2020 | $315.82 | 17 | Insmed, Inc. ($118.50) |
| 2019 | $442.05 | 26 | ViiV Healthcare Company ($220.32) |
| 2018 | $306.35 | 23 | ViiV Healthcare Company ($107.12) |
| 2017 | $341.24 | 17 | Merck Sharp & Dohme Corporation ($145.58) |
All Payment Transactions
114 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/02/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $33.80 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/16/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $120.96 | General |
| Category: HIV | ||||||
| 06/28/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: ANTIBIOTIC | ||||||
| 05/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.84 | General |
| 05/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.41 | General |
| 04/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.70 | General |
| 03/21/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/14/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: Infections and Infectious Diseases | ||||||
| 03/08/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/14/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.23 | General |
| 10/05/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.44 | General |
| 05/17/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $99.06 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/15/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $88.27 | General |
| Category: ANTIBIOTIC | ||||||
| 03/09/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.68 | General |
| 02/11/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $26.01 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/19/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.77 | General |
| 12/19/2022 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA, RECARBRIO | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/15/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $64.82 | General |
| Category: HIV | ||||||
| 12/15/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $38.69 | General |
| Category: HIV | ||||||
| 12/12/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: ANTIBIOTIC | ||||||
| 09/29/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.43 | General |
| 06/23/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $95.25 | General |
| Category: ANTIBIOTIC | ||||||
| 05/10/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.18 | General |
| 05/10/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 1,224 | 3,273 | $695,693 | $213,873 |
| 2022 | 4 | 1,372 | 3,506 | $786,580 | $212,874 |
| 2021 | 6 | 1,467 | 4,141 | $929,055 | $259,147 |
| 2020 | 7 | 1,448 | 4,119 | $924,490 | $259,127 |
Total Patients
5,511
Total Services
15,039
Medicare Billing
$945,021
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 722 | 2,668 | $504,953 | $155,665 | 30.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 350 | 384 | $119,121 | $36,060 | 30.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 86 | 154 | $43,788 | $13,674 | 31.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 66 | 67 | $27,831 | $8,474 | 30.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 813 | 2,838 | $553,410 | $148,808 | 26.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 407 | 458 | $160,300 | $44,487 | 27.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 96 | 154 | $45,430 | $11,698 | 25.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 56 | 56 | $27,440 | $7,881 | 28.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 831 | 3,201 | $624,195 | $174,047 | 27.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 439 | 494 | $173,025 | $49,939 | 28.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 94 | 162 | $47,790 | $12,665 | 26.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 75 | 81 | $39,690 | $12,000 | 30.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 16 | 191 | $42,975 | $10,140 | 23.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 12 | 12 | $1,380 | $355.68 | 25.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 806 | 3,104 | $605,435 | $169,815 | 28.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 416 | 470 | $164,500 | $47,687 | 29.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 92 | 178 | $52,510 | $14,021 | 26.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 88 | 89 | $43,610 | $13,714 | 31.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 15 | 238 | $53,550 | $12,471 | 23.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 12 | 19 | $2,470 | $815.14 | 33.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 19 | 21 | $2,415 | $602.74 | 25.0% |
About Dr. Ralph Villaran, M.D
Dr. Ralph Villaran, M.D is a Infectious Disease healthcare provider based in Highland, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699858985.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ralph Villaran, M.D has received a total of $2,661 in payments from pharmaceutical and medical device companies, with $438.83 received in 2024. These payments were reported across 114 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($2,447).
As a Medicare-enrolled provider, Villaran has provided services to 5,511 Medicare beneficiaries, totaling 15,039 services with total Medicare billing of $945,021. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Highland, IN
- Active Since 10/23/2006
- Last Updated 09/13/2012
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1699858985
Products in Payments
- DOVATO (Drug) $391.58
- Arikayce (Drug) $246.49
- NUZYRA (Drug) $242.02
- DIFICID (Drug) $209.56
- AVYCAZ (Drug) $189.25
- DALVANCE (Drug) $170.09
- REBYOTA (Biological) $125.00
- ZERBAXA (Drug) $107.50
- CABENUVA (Biological) $103.51
- TRIUMEQ (Drug) $96.89
- JULUCA (Drug) $74.54
- ISENTRESS (Drug) $52.70
- Cresemba (Drug) $34.12
- VIBATIV (Drug) $32.78
- TEFLARO (Drug) $26.01
- Santyl (Drug) $21.95
- MYCAMINE (Drug) $20.22
- Daraprim 30 Tablet in 1 Bottle (Drug) $19.53
- Vibativ (Drug) $16.44
- ClosureFast (Device) $15.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.